Polymyalgia Rheumatica (PMR) Special Interest Group at OMERACT 11: Outcomes of Importance for Patients with PMR

REFERENCES

1. 1.↵
   1. Crowson CS,
   2. Matteson EL,
   3. Myasoedova E,
   4. Michet CJ,
   5. Ernste FC,
   6. Warrington KJ,
   7. et al.

   The lifetime risk of adult-onset rheumatoid arthritis and other inflammatory autoimmune rheumatic diseases. Arthritis Rheum 2011;63:633–9.

   OpenUrlCrossRefPubMed
2. 2.↵
   1. Hutchings A,
   2. Hollywood J,
   3. Lamping DL,
   4. Pease CT,
   5. Chakravarty K,
   6. Silverman B,
   7. et al.

   Clinical outcomes, quality of life, and diagnostic uncertainty in the first year of polymyalgia rheumatica. Arthritis Rheum 2007;57:803–9.

   OpenUrlCrossRefPubMed
3. 3.↵
   1. Matteson EL

   . Clinical guidelines: unravelling the tautology of polymyalgia rheumatica. Nat Rev Rheumatol 2010;6:249–50.

   OpenUrlCrossRefPubMed
4. 4.↵
   1. Mackie SL,
   2. Hensor EM,
   3. Haugeberg G,
   4. Bhakta B,
   5. Pease CT

   . Can the prognosis of polymyalgia rheumatica be predicted at disease onset? Results from a 5-year prospective study. Rheumatology 2010;49:716–22.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   1. Dasgupta B,
   2. Borg FA,
   3. Hassan N,
   4. Barraclough K,
   5. Bourke B,
   6. Fulcher J,
   7. et al.

   BSR and BHPR guidelines for the management of polymyalgia rheumatica. Rheumatology 2010;49:186–90.

   OpenUrlFREE Full Text
6. 6.↵
   1. World Health Organization

   . International classification of functioning, disability and health: ICF, WHO, Geneva, Switzerland, 2001. [Internet. Accessed December 11, 2013.] Available from: http://www.who.int/classifications/icf/en/
7. 7.↵
   1. Dasgupta B,
   2. Salvarani C,
   3. Schirmer M,
   4. Crowson CS,
   5. Maradit-Kremers H,
   6. Hutchings A,
   7. et al.

   Developing classification criteria for polymyalgia rheumatica: comparison of views from an expert panel and wider survey. J Rheumatol 2008;35:270–7.

   OpenUrlAbstract/FREE Full Text
8. 8.↵
   1. Kirwan JR,
   2. Reeback JS

   . Stanford Health Assessment Questionnaire modified to assess disability in British patients with rheumatoid arthritis. Br J Rheumatol 1986;25:206–9.

   OpenUrlAbstract/FREE Full Text
9. 9.↵
   1. Hewlett S,
   2. Cockshott Z,
   3. Byron M,
   4. Kitchen K,
   5. Tipler S,
   6. Pope D,
   7. et al.

   Patients’ perceptions of fatigue in rheumatoid arthritis: overwhelming, uncontrollable, ignored. Arthritis Rheum 2005;53:697–702.

   OpenUrlCrossRefPubMed
10. 10.↵
    1. Minnock P,
    2. Kirwan J,
    3. Veale D,
    4. Fitzgerald O,
    5. Bresnihan B

    . Fatigue is an independent outcome measure and is sensitive to change in patients with psoriatic arthritis. Clin Exp Rheumatol 2010;28:401–4.

    OpenUrlPubMed
11. 11.↵
    1. Zigmond AS,
    2. Snaith RP

    . The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361–70.

    OpenUrlCrossRefPubMed
12. 12.↵
    1. Hewlett S,
    2. Wit Md,
    3. Richards P,
    4. Quest E,
    5. Hughes R,
    6. Heiberg T,
    7. et al.

    Patients and professionals as research partners: challenges, practicalities, and benefits. Arthritis Rheum 2006;55:676–80.

    OpenUrlCrossRefPubMed
13. 13.↵
    1. Chalmers I

    . Confronting therapeutic ignorance: tackling uncertainties about the effects of treatments will help to protect patients. BMJ 2008;337:a841.

    OpenUrlFREE Full Text
14. 14.↵
    1. Fries JF,
    2. Spitz PW,
    3. Kraines RG,
    4. Holman HR

    . Measurement of patient outcome in arthritis. Arthritis Rheum 1980;23:137–45.

    OpenUrlCrossRefPubMed
15. 15.↵
    1. Braun V,
    2. Clarke V

    . Using thematic analysis in psychology. Qual Res Psychol 2006;3:77–101.

    OpenUrlCrossRef
16. 16.↵
    1. Zakout S,
    2. Kirwan JR

    . Polymyalgia rheumatica has a nocturnal rise in serum interleukin-6 which is almost completely suppressed by nighttime prednisone [abstract]. Arthritis Rheum 2011;63 Suppl:S27.

    OpenUrl
17. 17.↵
    1. US Department of Health and Human Services Food and Drug Administration (FDA)

    . Guidance for industry — patient-reported outcome measures: use in medical product development to support labeling claims. [Internet. Accessed December 11, 2013.] Available from http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM193282.pdf